Skip to content

Mitopure™ (Proprietary Urolithin A) Bioavailability in Healthy Adults

Open-labelled, Crossover and Randomized Study With Mitopure™ (Proprietary Urolithin A) Dietary Supplementation Compared to Pomegranate Juice Intake: A Bioavailability Study in Healthy Adults (NOURISH)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04160312
Acronym
NOURISH
Enrollment
100
Registered
2019-11-13
Start date
2019-11-08
Completion date
2020-03-31
Last updated
2020-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Healthy Aging

Brief summary

This is a single-center, two-period, crossover, randomized, open labelled study enrolling 100 healthy subjects to evaluate the Urolithin A producer status and to compare bioavailabilty of direct dietary supplementation with Mitopure™ (proprietary Urolithin A) to dietary exposure with pomegranate juice

Interventions

DIETARY_SUPPLEMENTMitopure™ (Proprietary Urolithin A)

Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)

DIETARY_SUPPLEMENTPomegranate Juice

100% Pomegranate juice (approximately 1 glass equivalent)

Sponsors

Atlantia Food Clinical Trials
CollaboratorINDUSTRY
Amazentis SA
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Males and females 18 to 80 years of age; 2. Is in general good health, as determined by the clinical research team; 3. Willingness to consume investigational product, complete questionnaires and to complete all clinic visits; 4. Have given voluntary, written, informed consent to participant in the study;

Exclusion criteria

1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial; 2. Alcohol or drug abuse within the last 6 months; 3. Volunteers who plan to donate blood during the study or within 30 days of completing the study; 4. Subject has a known allergy to the test material's active or inactive ingredients; 5. Subjects with unstable medical conditions; 6. Clinically significant abnormal laboratory results at screening; 7. Participation in a clinical research trial within 30 days prior to randomization; 8. Allergy or sensitivity to study ingredients; lactose intolerance. 9. Individuals who are cognitively impaired and/or who are unable to give informed consent; 10. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject. 11. Has taken antibiotics within the previous 30 days;

Design outcomes

Primary

MeasureTime frame
Absolute change from T0 to T+24 hours in the Urolithin A (UA) group as compared to Pomegranate Juice (PJ) group in UA- glucuronide plasma levels.2 days

Secondary

MeasureTime frameDescription
Absolute change from T0 to T+6 hours in the UA group as compared to PJ group in UA- glucuronide plasma levels.1 day
Absolute change from T0 to T+6 hours in the UA group as compared to PJ group in UA- glucuronide blood spot levels.1 day
Change in AUC from T0 to T+6 and/or T+24 in the UA group as compared to the PJ group in UA glucuronide levels2 days
Absolute change from T0 to T6 hours and/or to T24 hours in the UA group as compared to PJ group in UA aglycone (parent) plasma levels2 days
Change in AUC from T0 to T+6 and/or T+24 in the UA group as compared to the PJ group in UA aglycone (parent) plasma levels2 days
Absolute change from T0 to T6 hours and/or to T24 hours in the UA group as compared to PJ group in UA sulfate plasma levels2 days
Change in AUC from T0 to T6 hours and/or to T24 hours in the UA group as compared to PJ group in UA sulfate plasma levels2 days
To assess prevalence of UA producers following consumption of fixed volume of Pomegranate juice in a healthy US population2 days
Absolute change from T0 to T+24 hours in the UA group as compared to PJ group in UA- glucuronide blood spot levels2 days
Differences between UA producers and non-producers at baseline for gait speed using the 4-meter gait speed test2 days
Differences between UA producers and non-producers at baseline for physical activity levels assessed via the International Physical Activity Questionnaire.2 daysQuestionnaire consists of questions that provide information on the physical activity in the last 7 days. Activities include total of duration and frequency from walking, moderate activity and severe physical activity. Accordingly,there are 3 activity levels: Inactive,minimal active and very active.The lowest level of physical activity is inactive and the highest level of physical activity is very active.
Differences between UA producers and non-producers at baseline for energy levels assessed via the Lee-Visual Analogue Scale to assess Fatigue (VAS-F).2 daysThe scale consists of 18 items relating to the subjective experience of fatigue. Scores fall between 0 (not fatigued at all) and 100 (extremely fatigued).
Differences between UA producers and non-producers at baseline for gut microbiome. Fecal samples will be used to extract DNA and shotgun sequencing will be performed to assess global microbiome differences at the species level.2 days
Differences between UA producers and non-producers at baseline for plasma metabolome. Metabolites in serum will be measured by metabolomic mass spectrometry2 days
Differences between UA producers and non-producers at baseline for blood biochemistry metabolic profile as assessed via lipid profile in plasma.2 days
Differences in consumer perception on the study investigation food products overall taste using a consumer perception Likert scale1 dayScale, of 1 to 5 where 1 is dislike extremely and 5 is like extremely
Differences between UA producers and non-producers at baseline for Hand grip strength using a calibrated JAMAR® Hydraulic Hand Dynamometer2 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026